<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03665402</url>
  </required_header>
  <id_info>
    <org_study_id>INH NAT2</org_study_id>
    <nct_id>NCT03665402</nct_id>
  </id_info>
  <brief_title>A Pharamcogenomic Study for Isoniazid According to NAT2 Polymorphism Status</brief_title>
  <official_title>Clinical Trial to Investigate the Appropriate Dose of Isoniazid According to NAT2 Polymorphism Status in Korean Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seoul National University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ministry of Health &amp; Welfare, Korea</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Seoul National University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A clinical trial to investigate the appropriate dose of isoniazid according to NAT2
      polymorphism status in Korean subjects
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 13, 2018</start_date>
  <completion_date type="Actual">March 31, 2019</completion_date>
  <primary_completion_date type="Actual">December 31, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Liver toxicity</measure>
    <time_frame>up to 4 weeks</time_frame>
    <description>Number of participants with drug-induced liver injury as assessed by below criteria.
AST or ALT &gt; 5 ULN
AST or ALT &gt; 3 ULN and total bilirubin &gt; 2 ULN (Hy's law case)
ALT ratio/ALP ratio &gt; 5</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Drug exposure</measure>
    <time_frame>Day 1 and day 29 0, 0.5, 1, 2, 3, 4, 6, 8, 12 and 24 post-dose</time_frame>
    <description>Plasma isoniazid concentration</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">16</enrollment>
  <condition>Tuberculosis</condition>
  <condition>Drug-Induced Liver Injury</condition>
  <condition>Adverse Drug Event</condition>
  <arm_group>
    <arm_group_label>Rapid metabolizer (Standard treatment)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Standard isoniazid dose regimen (300 mg qd)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Slow metabolizer (Standard treatment)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Standard isoniazid dose regimen (300 mg qd)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Slow metabolizer (PGx treatment)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Decreased isoniazid dose regimen (200 mg qd)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Isoniazid</intervention_name>
    <description>One of the first line anti-tubercolosis drug</description>
    <arm_group_label>Rapid metabolizer (Standard treatment)</arm_group_label>
    <arm_group_label>Slow metabolizer (PGx treatment)</arm_group_label>
    <arm_group_label>Slow metabolizer (Standard treatment)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Agreement with written informed consent

          -  Adult healthy male or female subject age 20 to 45

        Exclusion Criteria:

          -  Clinically significant, active gastrointestinal system, cardiovascular system,
             pulmonary system, renal system, endocrine system, blood system, digestive system,
             central nervous system, mental disease or malignancy

          -  Medication with any drug which may affect the pharmacokinetics of isoniazid within 14
             days

          -  Previously donate whole blood within 30 days or Previously participated in other trial
             within 60 days

          -  Subject with known for hypersensitivity reactions to isoniazid

          -  Subject who can not perform contraception during study periods

          -  Female woman who are pregnant or are breast feeding

          -  An impossible one who participates in clinical trial by investigator's decision
             including laboratory test result
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Seoul National University Hospital Clinical Trials Center</name>
      <address>
        <city>Seoul</city>
        <zip>110-744</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>December 2018</verification_date>
  <study_first_submitted>August 21, 2018</study_first_submitted>
  <study_first_submitted_qc>September 7, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">September 11, 2018</study_first_posted>
  <last_update_submitted>February 26, 2020</last_update_submitted>
  <last_update_submitted_qc>February 26, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 28, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tuberculosis</mesh_term>
    <mesh_term>Chemical and Drug Induced Liver Injury</mesh_term>
    <mesh_term>Drug-Related Side Effects and Adverse Reactions</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Isoniazid</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

